ALC.SW · Intrinsic value
Is Alcon Inc. (ALC.SW) overvalued or undervalued?
Alcon Inc. (ALC.SW) trades at the delayed market price of CHF 54.56 a share. That price already implies revenue growth of 12.4% a year for 5 years. TickerWorth's fair value is CHF 54.91 a share (priced within our range of CHF 38.67 – CHF 83.99). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is ALC.SW fairly valued?
- Fair value
- CHF 54.91
- Market price
- CHF 54.56
- Upside to fair value
- +0.6%
- Verdict
- Priced within our range of CHF 38.67 – CHF 83.99
Reverse DCF: Today's price implies revenue growth of 12.4% a year for 5 years; our model assumes 6.3% a year on average over the same horizon.
What is ALC.SW's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in Europe
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 44 of 100
Cheaper than 44% of Healthcare companies in Europe
- Price vs worth · 50 of 100
- Quality · 30 of 100
More profitable than 30% of Healthcare companies in Europe
- Financial health · 83 of 100
Financially stronger than 83% of Healthcare companies in Europe
- Growth · 63 of 100
Growing faster than 63% of Healthcare companies in Europe
- Momentum · 17 of 100
Outperformed 17% of Healthcare companies in Europe over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
ALC.SW DCF valuation, input by input
At a recent price of 54.56, Alcon Inc. (ALC.SW) trades roughly at TickerWorth's blended fair value of 54.91 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices ALC.SW in line with our estimate of what the business is intrinsically worth. Our fair value sits above the market, an implied +0.6% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values ALC.SW at about 39.50 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Alcon Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 8.2%, with a long-run terminal growth rate of 2.5%. About 77% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 12.4% annual revenue growth for ALC.SW. Our base case instead compounds to about 6.3% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, ALC.SW's modeled DCF value ranges from about 26.35 to 73.04 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Alcon Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of ALC.SW's intrinsic value. Figures update as new filings and prices come in.
Every input behind ALC.SW's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | 9,036,570,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 14.6% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 9% → 8% → 6% → 5% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.73 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 483M |
| Market priceLast known price · as of 2026-10-19 20:12 UTC | 54.56 |
Change ALC.SW's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Alcon Inc. do?
What does it do?
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in Switzerland. The company employs roughly 25,000 people.
How does it make money?
The business turns 10.9B in annual revenue into profit. Out of every $100 of sales, about $15 is left as operating profit (operating margin of 14.6%), after a 57% gross margin on the products/services it sells. After all costs, taxes and interest, 5.9% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.2× equity), comfortably covers its short-term bills (2.1× current ratio), and is currently profitable.
ALC.SW insider trading
Insider filings are available for US-listed companies only.
Common questions
What is ALC.SW's intrinsic value?
TickerWorth's blended fair value for Alcon Inc. (ALC.SW) is 54.91 per share, versus a market price of 54.56 (roughly at fair value).
Is ALC.SW overvalued or undervalued?
On our blended fair value ALC.SW looks in line with fair value at 54.56. This is an educational estimate, not advice.
What discount rate is used for ALC.SW?
A WACC of 8.2% and a terminal growth rate of 2.5%.
Is Alcon stock undervalued?
TickerWorth's fair value for Alcon Inc. (ALC.SW) is CHF 54.91 against a market price of CHF 54.56. Our read: Priced within our range of CHF 38.67 – CHF 83.99. This is a model estimate, not investment advice.
Alcon (ALC.SW) DCF valuation and fair value
Our fair value for Alcon Inc. (ALC.SW) is CHF 54.91, built on a 8.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Alcon stock?
Today's price implies revenue growth of 12.4% a year for 5 years; our model assumes 6.3% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of CHF 54.56. A model estimate, not investment advice.
Alcon (ALC.SW) insider trading
We have no recent SEC Form 4 insider filings on file for Alcon Inc. (ALC.SW). Form 4 covers US-listed companies only.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.